Next Article in Journal
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
Next Article in Special Issue
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
Previous Article in Journal
Are We Benign? What Can Wnt Signaling Pathway and Epithelial to Mesenchymal Transition Tell Us about Intracranial Meningioma Progression
Previous Article in Special Issue
Impact of Low-Dose Irradiation of the Lung and Heart on Toxicity and Pulmonary Function Parameters after Thoracic Radiotherapy
 
 

Order Article Reprints

Journal: Cancers, 2021
Volume: 13
Number: 1634

Article: Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
Authors: by Lavinia Monaco, Maria Gemelli, Irene Gotuzzo, Matteo Bauckneht, Cinzia Crivellaro, Carlo Genova, Diego Cortinovis, Lodovica Zullo, Luca Carlofrancesco Ammoni, Davide Paolo Bernasconi, Giovanni Rossi, Silvia Morbelli and Luca Guerra
Link: https://www.mdpi.com/2072-6694/13/7/1634

MDPI provides article reprints in high quality with convenient shipping to destinations worldwide. The articles are printed in on premium paper with high-resolution figures. Our covers are customized to your article and designed to be complimentary to the journal. These reprints are ideal additions to your portfolio. Copy details: 135g/m2 paper, 2x stitched, full colour and glossy finish, orderable in quantities from 10 to 1000.

If you have any questions, or special requests, please write to our support team; we are happy to provide you with the information you need.

Reprint Options

If you need more than 400 copies, please contact us by e-mail (articlereprints@mdpi.com) and we will prepare an individual offer for you.

Order Cost and Details

Contact Person

Invoice Address

Notes or Comments

Validate and Place Order

The order must be prepaid after it is placed

req denotes required fields.
Back to TopTop